These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 23891738)

  • 1. Medulloblastoma expresses CD1d and can be targeted for immunotherapy with NKT cells.
    Liu D; Song L; Brawley VS; Robison N; Wei J; Gao X; Tian G; Margol A; Ahmed N; Asgharzadeh S; Metelitsa LS
    Clin Immunol; 2013 Oct; 149(1):55-64. PubMed ID: 23891738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic implications of CD1d expression and tumor-infiltrating macrophages in pediatric medulloblastomas.
    Teo WY; Elghetany MT; Shen J; Man TK; Li X; Chintagumpala M; Su JM; Dauser R; Whitehead W; Adesina AM; Lau CC
    J Neurooncol; 2014 Nov; 120(2):293-301. PubMed ID: 25115738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD1d expression in glioblastoma is a promising target for NKT cell-based cancer immunotherapy.
    Hara A; Koyama-Nasu R; Takami M; Toyoda T; Aoki T; Ihara F; Kobayashi M; Hirono S; Matsutani T; Nakayama T; Iwadate Y; Motohashi S
    Cancer Immunol Immunother; 2021 May; 70(5):1239-1254. PubMed ID: 33128583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans.
    Metelitsa LS
    Clin Immunol; 2011 Aug; 140(2):119-29. PubMed ID: 21095162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defining a novel subset of CD1d-dependent type II natural killer T cells using natural killer cell-associated markers.
    Singh AK; Rhost S; Löfbom L; Cardell SL
    Scand J Immunol; 2019 Sep; 90(3):e12794. PubMed ID: 31141185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages.
    Song L; Asgharzadeh S; Salo J; Engell K; Wu HW; Sposto R; Ara T; Silverman AM; DeClerck YA; Seeger RC; Metelitsa LS
    J Clin Invest; 2009 Jun; 119(6):1524-36. PubMed ID: 19411762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoptive immunotherapy mediated by ex vivo expanded natural killer T cells against CD1d-expressing lymphoid neoplasms.
    Bagnara D; Ibatici A; Corselli M; Sessarego N; Tenca C; De Santanna A; Mazzarello A; Daga A; Corvò R; De Rossi G; Frassoni F; Ciccone E; Fais F
    Haematologica; 2009 Jul; 94(7):967-74. PubMed ID: 19454494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ex vivo induction and expansion of natural killer T cells by CD1d1-Ig coated artificial antigen presenting cells.
    Webb TJ; Bieler JG; Schneck JP; Oelke M
    J Immunol Methods; 2009 Jul; 346(1-2):38-44. PubMed ID: 19446558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Adaptor Proteins in the Biology of Natural Killer T (NKT) Cells.
    Gerth E; Mattner J
    Front Immunol; 2019; 10():1449. PubMed ID: 31293596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complementary approaches to study NKT cells in cancer.
    Berzofsky JA; Olkhanud PB; Terabe M
    Methods Enzymol; 2020; 631():371-389. PubMed ID: 31948558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bcl-xL regulates CD1d-mediated antigen presentation to NKT cells by altering CD1d trafficking through the endocytic pathway.
    Subrahmanyam PB; Carey GB; Webb TJ
    J Immunol; 2014 Sep; 193(5):2096-105. PubMed ID: 25070854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo.
    Tian G; Courtney AN; Jena B; Heczey A; Liu D; Marinova E; Guo L; Xu X; Torikai H; Mo Q; Dotti G; Cooper LJ; Metelitsa LS
    J Clin Invest; 2016 Jun; 126(6):2341-55. PubMed ID: 27183388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Artificial antigen presenting cell (aAPC) mediated activation and expansion of natural killer T cells.
    East JE; Sun W; Webb TJ
    J Vis Exp; 2012 Dec; (70):. PubMed ID: 23299308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted disruption of CD1d prevents NKT cell development in pigs.
    Yang G; Artiaga BL; Hackmann TJ; Samuel MS; Walters EM; Salek-Ardakani S; Driver JP
    Mamm Genome; 2015 Jun; 26(5-6):264-70. PubMed ID: 25930071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interview: glycolipid antigen presentation by CD1d and the therapeutic potential of NKT cell activation.
    Kronenberg M
    J Vis Exp; 2007; (10):635. PubMed ID: 18989407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Potent CD1d-binding Glycolipid for iNKT-Cell-based Therapy Against Human Breast Cancer.
    Seki T; Liu J; Brutkiewicz RR; Tsuji M
    Anticancer Res; 2019 Feb; 39(2):549-555. PubMed ID: 30711929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD1d activation and blockade: a new antitumor strategy.
    Teng MW; Yue S; Sharkey J; Exley MA; Smyth MJ
    J Immunol; 2009 Mar; 182(6):3366-71. PubMed ID: 19265113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD1d-Restricted Type II NKT Cells Reactive With Endogenous Hydrophobic Peptides.
    Nishioka Y; Masuda S; Tomaru U; Ishizu A
    Front Immunol; 2018; 9():548. PubMed ID: 29599785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD1d-dependent NKT cells play a protective role in acute and chronic arthritis models by ameliorating antigen-specific Th1 responses.
    Teige A; Bockermann R; Hasan M; Olofsson KE; Liu Y; Issazadeh-Navikas S
    J Immunol; 2010 Jul; 185(1):345-56. PubMed ID: 20525883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A molecular basis for NKT cell recognition of CD1d-self-antigen.
    Mallevaey T; Clarke AJ; Scott-Browne JP; Young MH; Roisman LC; Pellicci DG; Patel O; Vivian JP; Matsuda JL; McCluskey J; Godfrey DI; Marrack P; Rossjohn J; Gapin L
    Immunity; 2011 Mar; 34(3):315-26. PubMed ID: 21376640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.